The Annals of pharmacotherapy · 2026
Clinical Evaluation of Bysanti: A New Atypical Antipsychotic for Schizophrenia and Bipolar I Disorder.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Phillips Bradley, Horta Melanie, Santini Nicole, Chapman Derek
Аннотация
OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, safety, and clinical role of milsaperidone (Bysanti), a newly approved atypical antipsychotic for schizophrenia and acute bipolar I disorder.
DATA SOURCES: A comprehensive literature search was conducted using PubMed, Embase, and Google Scholar from database inception through April 2026. Additional data were obtained from Food and Drug Administration prescribing information and pharmacologic references using key terms including milsaperidone, Bysanti, iloperidone, atypical antipsychotics, schizophrenia, and bipolar I disorder.
STUDY SELECTION AND DATA ABSTRACTION: English-language studies evaluating milsaperidone or its parent compound, iloperidone, were included, focusing on pharmacologic properties, clinical efficacy, and safety outcomes. Key trials, reviews, and regulatory data were abstracted and synthesized.
DATA SYNTHESIS: Milsaperidone, the active metabolite of iloperidone, exerts its effects through dopamine D₂ and serotonin 5-HT₂A receptor antagonism, with additional α₁-adrenergic blockade contributing to its safety profile. Clinical evidence demonstrates efficacy in reducing symptoms of schizophrenia and bipolar mania, with low rates of extrapyramidal symptoms and akathisia. However, tolerability concerns include orthostatic hypotension, QTc prolongation, sedation, and weight gain. Pharmacokinetic variability associated with CYP2D6 metabolism and gradual titration remain key considerations.Relevance to Patient Care and Clinical Practice in Comparison With Existing Drugs:Milsaperidone expands available atypical antipsychotic options, offering a potentially favorable tolerability profile for patients with prior intolerance or sensitivity to movement-related adverse effects. Careful patient selection and monitoring are essential.
CONCLUSION: Milsaperidone represents an incremental yet meaningful addition to antipsychotic therapy, supporting individualized strategies in schizophrenia and bipolar I disorder while balancing efficacy and tolerability.
DATA SOURCES: A comprehensive literature search was conducted using PubMed, Embase, and Google Scholar from database inception through April 2026. Additional data were obtained from Food and Drug Administration prescribing information and pharmacologic references using key terms including milsaperidone, Bysanti, iloperidone, atypical antipsychotics, schizophrenia, and bipolar I disorder.
STUDY SELECTION AND DATA ABSTRACTION: English-language studies evaluating milsaperidone or its parent compound, iloperidone, were included, focusing on pharmacologic properties, clinical efficacy, and safety outcomes. Key trials, reviews, and regulatory data were abstracted and synthesized.
DATA SYNTHESIS: Milsaperidone, the active metabolite of iloperidone, exerts its effects through dopamine D₂ and serotonin 5-HT₂A receptor antagonism, with additional α₁-adrenergic blockade contributing to its safety profile. Clinical evidence demonstrates efficacy in reducing symptoms of schizophrenia and bipolar mania, with low rates of extrapyramidal symptoms and akathisia. However, tolerability concerns include orthostatic hypotension, QTc prolongation, sedation, and weight gain. Pharmacokinetic variability associated with CYP2D6 metabolism and gradual titration remain key considerations.Relevance to Patient Care and Clinical Practice in Comparison With Existing Drugs:Milsaperidone expands available atypical antipsychotic options, offering a potentially favorable tolerability profile for patients with prior intolerance or sensitivity to movement-related adverse effects. Careful patient selection and monitoring are essential.
CONCLUSION: Milsaperidone represents an incremental yet meaningful addition to antipsychotic therapy, supporting individualized strategies in schizophrenia and bipolar I disorder while balancing efficacy and tolerability.